Hospital Virgen de la Arrixaca

El Palmar 30120

0 studies enrolling now · 6 studies all time

What they study most

Alport Syndrome, Complete Response, Epithelial Ovarian Cancer, FIGO Stage III-IV, Fallopian Tube Cancer, Follicular Lymphoma, Heart Failure With Left Bundle Branch Block, Lung Cancer, Newly Diagnosed, Partial Response, Primary Peritoneal, Refractory Follicular Lymphoma

Studies at this site

• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) — Completed
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — Completed
• AdaptResponse Clinical Trial — Completed
• Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission — Completed